Diabetes Therapy

Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN)

By Linong Ji, Liming Chen, Zhifeng Cheng, Isabel M. Kloer

Trial in 306 peopleInterventions

76 weeks, randomised, double-blind, placebo-controlled, multicentre, registered NCT06214741

The paper

Linong Ji, Liming Chen, Zhifeng Cheng, Isabel M. Kloer

Peking University People's Hospital; Boehringer Ingelheim (Germany)

Diabetes Therapy, 14 Aug 2026

doi.org/10.1007/s13300-026-01908-x PubMed 42599381

Nutrients4 Oct 2026
Nutrient deficits linked to higher metabolic risks in obesity
Cardiology and Therapy4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety